Kilburn, L., Landi, D., Leary, S., Ziegler, D., Baxter, P., Franson, A., McCowage, G., Waanders, A., Van der Lugt, J., Oren, M. Y., Gerber, N., Gottardo, N., Khuong-Quang, D., Nysom, K., Bailey, S., Driever, P. H., Perreault, S., Witt, O., Hahn, S., Hargrave, D., Hassall, T., Jabado, N., Kang, H. J., Larouche, V., Toledano, H., Kline, C., Abdelbaki, M., Chi, S., Gardner, S., Whipple, N., Mueller, S., Blackman, S., Zhao, X., Da Costa, D., Cox, M., Packer, R., & Hansford, J. (n.d.). cTNI-68. FIREFLY-1 (PNOC026): PHASE 2 STUDY OF PAN-RAF INHIBITOR TOVORAFENIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RAF-ALTERED RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA OR ADVANCED SOLID TUMORS. Neuro-oncology, 24, vii89. http://access.bl.uk/ark:/81055/vdc_100169741480.0x000010